StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on Rani Therapeutics (RANI)

Fri, 21 Aug 2026 06:59:31 -0400

H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating and $11.00 price target on Rani Therapeutics (NASDAQ: RANI).

The analyst commented: "The quarter was financially clean, with EPS of $(0.04) ahead of FactSet’s $(0.05), R&D expense of $5.0M below FactSet’s $5.5M, and $53.4M of cash and marketable securities at quarter-end. More important for the stock, RANI has now dosed the first participants in the RT-114 Phase 1a expansion cohort, expects additional data by YE26 and continues to target initiation of the eight-week Phase 1b obesity study by YE26, with data expected in 2027. Following the >150% relative bioavailability achieved with a

Chardan Starts Rani Therapeutics (RANI) at Buy

Tue, 18 Aug 2026 07:12:23 -0400

Chardan analyst Andreas Argyrides initiates coverage on Rani Therapeutics (NASDAQ: RANI) with a Buy rating and a price target of $6.00.

For an analyst ratings summary and ratings history on Rani Therapeutics click here. For more ratings news on Rani Therapeutics click here.

Shares of Rani Therapeutics closed at $0.80 yesterday.

Form SCHEDULE 13G/A Rani Therapeutics Holdin Filed by: RA CAPITAL MANAGEMENT, L.P.

Fri, 14 Aug 2026 16:50:00 -0400

si-local-file:///var/storage/secattach/20260814/26932196.html

Form SCHEDULE 13G/A Rani Therapeutics Holdin Filed by: RA CAPITAL MANAGEMENT, L.P.

Fri, 14 Aug 2026 16:50:00 -0400

si-local-file:///var/storage/secattach/20260814/26932196.html

Form 10-Q Rani Therapeutics Holdin For: Jun 30

Thu, 13 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260813/26921446.html

Form 10-Q Rani Therapeutics Holdin For: Jun 30

Thu, 13 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260813/26921446.html

Rani Therapeutics Holdings, Inc. (RANI) Tops Q2 EPS by 1c

Thu, 13 Aug 2026 16:15:47 -0400

Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) reported Q2 EPS of ($0.04), $0.01 better than the analyst estimate of ($0.05). Revenue for the quarter came in at $1.7 million versus the consensus estimate of $500 thousand.

For earnings history and earnings-related data on Rani Therapeutics Holdings, Inc. (RANI) click here.

Form 8-K Rani Therapeutics Holdin For: Aug 13

Thu, 13 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260813/26921150.html

Form 8-K Rani Therapeutics Holdin For: Aug 13

Thu, 13 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260813/26921150.html

Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update

Thu, 13 Aug 2026 16:05:00 -0400

~ Continues to advance RT-114 in the clinic with first participants dosed in the Phase 1a expansion cohort; additional data expected by end of 2026 ~

~ Announced positive initial Phase 1a data for RT-114, with oral bioavailability achieving systemic exposure greater than 150% relative to matched subcutaneous dosing ~

~ Completed a $20 million registered direct offering ~

~ Expanded obesity pipeline through new research and development collaboration with PegBio to explore oral delivery of novel obesity and metabolic disease molecules using the RaniPill® platform ~

~ Appointed Nicholas Maestas

Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update

Thu, 13 Aug 2026 16:05:00 -0400

~ Continues to advance RT-114 in the clinic with first participants dosed in the Phase 1a expansion cohort; additional data expected by end of 2026 ~

~ Announced positive initial Phase 1a data for RT-114, with oral bioavailability achieving systemic exposure greater than 150% relative to matched subcutaneous dosing ~

~ Completed a $20 million registered direct offering ~

~ Expanded obesity pipeline through new research and development collaboration with PegBio to explore oral delivery of novel obesity and metabolic disease molecules using the RaniPill® platform ~

~ Appointed Nicholas Maestas

Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update

Thu, 13 Aug 2026 16:05:00 -0400

~ Continues to advance RT-114 in the clinic with first participants dosed in the Phase 1a expansion cohort; additional data expected by end of 2026 ~

~ Announced positive initial Phase 1a data for RT-114, with oral bioavailability achieving systemic exposure greater than 150% relative to matched subcutaneous dosing ~

~ Completed a $20 million registered direct offering ~

~ Expanded obesity pipeline through new research and development collaboration with PegBio to explore oral delivery of novel obesity and metabolic disease molecules using the RaniPill® platform ~

~ Appointed Nicholas Maestas

Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update

Thu, 13 Aug 2026 16:05:00 -0400

~ Continues to advance RT-114 in the clinic with first participants dosed in the Phase 1a expansion cohort; additional data expected by end of 2026 ~

~ Announced positive initial Phase 1a data for RT-114, with oral bioavailability achieving systemic exposure greater than 150% relative to matched subcutaneous dosing ~

~ Completed a $20 million registered direct offering ~

~ Expanded obesity pipeline through new research and development collaboration with PegBio to explore oral delivery of novel obesity and metabolic disease molecules using the RaniPill® platform ~

~ Appointed Nicholas Maestas

Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update

Thu, 13 Aug 2026 16:05:00 -0400

~ Continues to advance RT-114 in the clinic with first participants dosed in the Phase 1a expansion cohort; additional data expected by end of 2026 ~

~ Announced positive initial Phase 1a data for RT-114, with oral bioavailability achieving systemic exposure greater than 150% relative to matched subcutaneous dosing ~

~ Completed a $20 million registered direct offering ~

~ Expanded obesity pipeline through new research and development collaboration with PegBio to explore oral delivery of novel obesity and metabolic disease molecules using the RaniPill® platform ~

~ Appointed Nicholas Maestas

Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update

Thu, 13 Aug 2026 16:05:00 -0400

~ Continues to advance RT-114 in the clinic with first participants dosed in the Phase 1a expansion cohort; additional data expected by end of 2026 ~

~ Announced positive initial Phase 1a data for RT-114, with oral bioavailability achieving systemic exposure greater than 150% relative to matched subcutaneous dosing ~

~ Completed a $20 million registered direct offering ~

~ Expanded obesity pipeline through new research and development collaboration with PegBio to explore oral delivery of novel obesity and metabolic disease molecules using the RaniPill® platform ~

~ Appointed Nicholas Maestas

Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update

Thu, 13 Aug 2026 16:05:00 -0400

~ Continues to advance RT-114 in the clinic with first participants dosed in the Phase 1a expansion cohort; additional data expected by end of 2026 ~

~ Announced positive initial Phase 1a data for RT-114, with oral bioavailability achieving systemic exposure greater than 150% relative to matched subcutaneous dosing ~

~ Completed a $20 million registered direct offering ~

~ Expanded obesity pipeline through new research and development collaboration with PegBio to explore oral delivery of novel obesity and metabolic disease molecules using the RaniPill® platform ~

~ Appointed Nicholas Maestas

Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update

Thu, 13 Aug 2026 16:05:00 -0400

~ Continues to advance RT-114 in the clinic with first participants dosed in the Phase 1a expansion cohort; additional data expected by end of 2026 ~

~ Announced positive initial Phase 1a data for RT-114, with oral bioavailability achieving systemic exposure greater than 150% relative to matched subcutaneous dosing ~

~ Completed a $20 million registered direct offering ~

~ Expanded obesity pipeline through new research and development collaboration with PegBio to explore oral delivery of novel obesity and metabolic disease molecules using the RaniPill® platform ~

~ Appointed Nicholas Maestas

Rani Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

Mon, 10 Aug 2026 08:00:00 -0400

SAN JOSE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced that the company’s management team will participate in the upcoming Canaccord Genuity 46th Annual Growth Conference. Details below:

Canaccord Genuity 46th Annual Growth Conference
Date: Wednesday, August 12, 2026 at 2:30pm E.T.
Location: Boston, MA
Presenter: Chief Executive Officer, Talat Imran, and Chief Financial Officer, Nicholas Maestas
Format: Presentation and 1x1 Meetings

Interested parties can access the live webcast for this conference from the Investor Relations section

Rani Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

Mon, 10 Aug 2026 08:00:00 -0400

SAN JOSE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced that the company’s management team will participate in the upcoming Canaccord Genuity 46th Annual Growth Conference. Details below:

Canaccord Genuity 46th Annual Growth Conference
Date: Wednesday, August 12, 2026 at 2:30pm E.T.
Location: Boston, MA
Presenter: Chief Executive Officer, Talat Imran, and Chief Financial Officer, Nicholas Maestas
Format: Presentation and 1x1 Meetings

Interested parties can access the live webcast for this conference from the Investor Relations section

Rani Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

Mon, 10 Aug 2026 08:00:00 -0400

SAN JOSE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced that the company’s management team will participate in the upcoming Canaccord Genuity 46th Annual Growth Conference. Details below:

Canaccord Genuity 46th Annual Growth Conference
Date: Wednesday, August 12, 2026 at 2:30pm E.T.
Location: Boston, MA
Presenter: Chief Executive Officer, Talat Imran, and Chief Financial Officer, Nicholas Maestas
Format: Presentation and 1x1 Meetings

Interested parties can access the live webcast for this conference from the Investor Relations section

Rani Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

Mon, 10 Aug 2026 08:00:00 -0400

SAN JOSE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced that the company’s management team will participate in the upcoming Canaccord Genuity 46th Annual Growth Conference. Details below:

Canaccord Genuity 46th Annual Growth Conference
Date: Wednesday, August 12, 2026 at 2:30pm E.T.
Location: Boston, MA
Presenter: Chief Executive Officer, Talat Imran, and Chief Financial Officer, Nicholas Maestas
Format: Presentation and 1x1 Meetings

Interested parties can access the live webcast for this conference from the Investor Relations section

Rani Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

Mon, 10 Aug 2026 08:00:00 -0400

SAN JOSE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced that the company’s management team will participate in the upcoming Canaccord Genuity 46th Annual Growth Conference. Details below:

Canaccord Genuity 46th Annual Growth Conference
Date: Wednesday, August 12, 2026 at 2:30pm E.T.
Location: Boston, MA
Presenter: Chief Executive Officer, Talat Imran, and Chief Financial Officer, Nicholas Maestas
Format: Presentation and 1x1 Meetings

Interested parties can access the live webcast for this conference from the Investor Relations section

Rani Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

Mon, 10 Aug 2026 08:00:00 -0400

SAN JOSE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced that the company’s management team will participate in the upcoming Canaccord Genuity 46th Annual Growth Conference. Details below:

Canaccord Genuity 46th Annual Growth Conference
Date: Wednesday, August 12, 2026 at 2:30pm E.T.
Location: Boston, MA
Presenter: Chief Executive Officer, Talat Imran, and Chief Financial Officer, Nicholas Maestas
Format: Presentation and 1x1 Meetings

Interested parties can access the live webcast for this conference from the Investor Relations section

Rani Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

Mon, 10 Aug 2026 08:00:00 -0400

SAN JOSE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced that the company’s management team will participate in the upcoming Canaccord Genuity 46th Annual Growth Conference. Details below:

Canaccord Genuity 46th Annual Growth Conference
Date: Wednesday, August 12, 2026 at 2:30pm E.T.
Location: Boston, MA
Presenter: Chief Executive Officer, Talat Imran, and Chief Financial Officer, Nicholas Maestas
Format: Presentation and 1x1 Meetings

Interested parties can access the live webcast for this conference from the Investor Relations section

Rani Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

Mon, 10 Aug 2026 08:00:00 -0400

SAN JOSE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced that the company’s management team will participate in the upcoming Canaccord Genuity 46th Annual Growth Conference. Details below:

Canaccord Genuity 46th Annual Growth Conference
Date: Wednesday, August 12, 2026 at 2:30pm E.T.
Location: Boston, MA
Presenter: Chief Executive Officer, Talat Imran, and Chief Financial Officer, Nicholas Maestas
Format: Presentation and 1x1 Meetings

Interested parties can access the live webcast for this conference from the Investor Relations section